Dublin, April 02, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.
Inflammatory Bowel Disease Treatment Market is expected to reach US$ 33.99 billion 2033 from US$ 22.91 billion in 2024, with a CAGR of 4.48% from 2025 to 2033.
Globally, the use of treatments for inflammatory bowel disease is rising as more people become aware of the advantages of medications including biologics, corticosteroids, and others. According to a study by Science Direct, for example, of the 655 patients in South America, 36.4% of those with Crohn's disease and 9.1% of those with ulcerative colitis utilized biological therapy.
Growth Drivers for the Inflammatory Bowel Disease Treatment Market
A robust pipeline molecule portfolio is expected to boost product launches over the forecast period.
Some of the factors driving the growth of the inflammatory bowel disease treatment market include the increasing prevalence of Crohn's disease and ulcerative colitis as well as the growing global awareness of the condition. As a result, a number of significant industry participants are concentrating on research and development and investigating novel treatment options for IBD.
For instance, there are now around 145 active clinical trials for Crohn's disease and ulcerative colitis, according to ClinicalTrials.gov. Most of the compounds are in clinical trials in phases three and four. To develop and market PF-06480605 (now RVT-3101), Roivant Sciences established a new Vant in December 2022. A completely human monoclonal antibody called RVT-3101 targets TL1A and is presently being developed in Phase 2b for ulcerative colitis (UC). Pfizer and The Vant have the only right to work together on a next-generation TL1A-directed antibody that just went into Phase 1.
Phase 3 clinical trials were conducted by Eli Lilly and Company to assess the long-term safety and effectiveness of mirikizumab in children and adolescents with Crohn's disease or moderate-to-severe ulcerative colitis.
Furthermore, the growing need for biologics to treat various ailments has prompted market participants to diversify their product lines and launch their medications internationally. Therefore, it is anticipated that the adoption of inflammatory bowel disease therapies would be supported during the forecast period by the growing regulatory approvals for the drugs introduced by the major companies as well as the growing patient preferences for the prescriptions.
Improved diagnostics
Better diagnostics, which allow for earlier detection and more precise disease monitoring, are a major growth driver for the market for drugs to treat inflammatory bowel disease (IBD). More accurate IBD diagnosis and prompt intervention are made possible by genetic profiling, biomarker-based blood testing, and advanced imaging techniques. Personalized therapy plans made possible by early diagnosis improve patient outcomes. The market for tailored and cutting-edge therapeutics for IBD is driven by the improved disease management brought about by evolving diagnostic tools, which also lower hospitalizations and consequences.
Advancements in biologic therapies
One of the main factors propelling the market for treatments for inflammatory bowel disease (IBD) is the development of biologic medicines. For moderate to severe cases of IBD, biologics like TNF inhibitors (e.g., infliximab, adalimumab) and more recent drugs that target particular immune pathways (e.g., integrin inhibitors, IL-12/23 inhibitors) provide tailored therapeutic choices. Compared to conventional medications, these treatments are more successful in achieving long-term remission and improving patients' quality of life. Biologic therapies are becoming more and more popular in the treatment of IBD due to their improved efficacy and decreased side effects, which is propelling market growth and promoting further study and investment in novel treatments.
In June 2021, AbbVie declared that SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, has been authorized by the US FDA to treat individuals with moderately to highly active Crohn's disease (CD). Furthermore, in October 2023, Teva Pharmaceuticals and Sanofi worked together to co-develop and co-commercialize asset TEV'574, which is presently undergoing Phase 2b clinical studies to treat Crohn's disease and ulcerative colitis, two forms of inflammatory bowel disease.
Challenges in the Inflammatory Bowel Disease Treatment Market
Drugs' exorbitant costs and lax reimbursement guidelines will limit market expansion.
The number of patients receiving treatment for inflammatory bowel disease is lower in underdeveloped nations due to a lack of knowledge about the condition. Furthermore, it is anticipated that in the upcoming years, patients' use of inflammatory bowel disease treatments will be restricted due to the high cost of therapy, which includes both medication and additional expenses.
The yearly mean expenditure per patient for UC and CD in the United States ranged from USD 6217 to USD 11,477 and USD 11,034 to USD 18,932, respectively, according to a 2023 study published in BMC Gastroenterology.
Furthermore, biologics are being used more frequently to treat Crohn's disease and ulcerative colitis; nevertheless, the high expense of biologics treatment is restricting market expansion. For instance, in the United Kingdom, Adalimumab costs around USD 12,343 per person annually, according to the National Center for Biotechnology Information (NCBI).
The lack of reimbursement for IBD therapy in developing nations like China, Russia, and India restricts the use of these medications in the area. Thus, the demand for inflammatory bowel disease treatments is being constrained by the high cost of inflammatory bowel disease drugs and the absence of reimbursement schemes in underdeveloped nations.
High treatment costs
The market for treatments for inflammatory bowel disease (IBD) is severely hampered by high treatment costs. Patients and healthcare systems may experience financial difficulty due to the high cost of biologic therapy, which are frequently the most effective treatments. Access to necessary therapies may be restricted by these expenses, particularly in areas with low or middling incomes. Widespread adoption is hampered by the high cost of pharmaceuticals and the need for continuous therapy. Furthermore, inadequate insurance coverage may lead to patients delaying or skipping necessary care, which could have an impact on the course of therapy.
Inflammatory Bowel Disease Treatment Market Overview by Regions
The market for treatments for inflammatory bowel disease (IBD) is growing worldwide, with North America leading the way thanks to its sophisticated healthcare system, high treatment uptake, and significant research expenditures. With increased knowledge and accessibility to biologic treatments, Europe is a close follower. Due to rising IBD prevalence and better access to healthcare, the Asia-Pacific region is expanding quickly. Despite their slower adoption rates, the Middle East and Africa are steadily growing as awareness and healthcare systems advance. Treatment availability, economic factors, and healthcare access all affect regional disparities.
Company Analysis: Overview, Key Persons, Recent Development & Strategies, Product Portfolio, Financial Insights
- Abbott Laboratories
- AbbVie Inc.
- Allergan Therapeutics LLC
- Bausch Health Companies Inc. (Salix Pharmaceuticals)
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Novartis AG
- Pfizer Inc.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $22.91 Billion |
| Forecasted Market Value (USD) by 2033 | $33.99 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
Key Topics Covered:
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Inflammatory Bowel Disease Treatment Market
6. Market Share Analysis
6.1 Drug Class
6.2 Disease Indication
6.3 Distribution Channel
6.4 Country
7. Drug Class
7.1 TNF Inhibitors
7.2 Anti-Integrin
7.3 IL inhibitors
7.4 JAK inhibitors
7.5 Corticosteroids
7.6 Aminosalicylates
7.7 Others
8. Disease Indication
8.1 Ulcerative Colitis
8.2 Crohn's Disease
9. Distribution Channel
9.1 Hospital Pharmacy
9.2 Retail Pharmacy
9.3 Online Pharmacy
10. Country
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Thailand
10.3.7 Malaysia
10.3.8 Indonesia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 UAE
11. Porter's Five Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Company Analysis
For more information about this report visit https://www.researchandmarkets.com/r/pta5g0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
